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OBJECTIVE: Estimate the provider time allocated to the
management of anaemia with rHuEPO in dialysis centres
throughout Europe. METHOD: The same time and
motion protocol was used in nine dialysis centres in ﬁve
European countries (Netherlands, Germany, France,
Spain and Italy). Structured interviews with key person-
nel were used to obtain an overview of all rHuEPO
related activities performed by physician, nurse, health
auxiliaries, lab and pharmacy personnel. Strict start and
end points were deﬁned for frequent activities (n/week >
1). Time devoted to these activities was measured by a
trained centre nurse with a chronometer. Time devoted to
less frequent activities (n/week < 1) was estimated from
interviews. Nurse and physician time analysis by dialysis
centre is reported. To compare time measured across 
the different centres, activities were regrouped into three
main tasks for nurses (rHuEPO administration; blood
sampling; other rHuEPO management) and two for
physicians (anaemia monitoring and drug & blood 
prescription). RESULTS: Average time for rHuEPO 
management per session by nurse and physician com-
bined was 3min 52sec (Min: 1min 47sec; Max: 6min 
34sec). The observed time differences were explained by
the differences in tasks to be accomplished by nurses such
as getting drug and lab prescriptions, lab results, supplies,
billing the drug, getting the drug from pharmacy. Esti-
mated average time per year for rHuEPO management 
of 50 dialysis patients with 3 rHuEPO sessions per week
is therefore 503 hours ((3.87min ¥ 50 ¥ 3 ¥ 52)/60).
Switching to one session per week with darbepoetin alfa
(AranespTM) will gain an estimated 350 hours per year for
nurse and physician combined. CONCLUSION: With
fewer injections needed with AranespTM for anaemia man-
agement in dialyses centres, substantial time gain per year
may occur in each centre.
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OBJECTIVES: We examined the incremental cost of
CKD over a 66-month period, and the contribution 
of CKD-related comorbidity to the cost of care.
METHODS: Using electronic medical record data at a
large HMO, we calculated inpatient, outpatient, phar-
macy and total costs for 13,796 cases and 13,796
matched (age and gender) controls. Cases were patients
whose glomerular ﬁltration rates (GFR, ml/min/1.72m2)
were <90 on two consecutive measurements (at least 90
days apart) in 1996. Cases were divided into stages 2, 3
and 4 based on new guidelines from the National Kidney
Foundation. Patients were followed until death, initiation
of renal replacement therapy (RRT), or July 1, 2001.
CKD-related comorbidities were identiﬁed (diabetes, con-
gestive heart failure, coronary artery disease, anemia and
hypertension) based on ICD9 codes. RESULTS: Patients
with CKD were 1.9 to 2.5 times more likely (depending
on stage) than controls to have been treated with pre-
scription drugs, had more outpatient visits (1.3 to 1.9
times more than controls, across stages), and had 1.8 to
3.1 more inpatient stays than did controls. CKD-related
comorbidities almost double the total cost of care for
both cases and controls, and cases with no CKD-related
comorbidities are about twice as expensive to manage as
controls with no CKD-related comorbidities. CONCLU-
SION: We found that CKD doubles costs to the health
care system, and that comorbidities related to CKD con-
tribute more to the cost of managing these patients than
does CKD alone. Future research in this area could be
usefully directed toward analyzing the clinical and eco-
nomic consequences of better managing patients with
CKD.
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WHERE ARE THE COST SAVINGS?
Pirk O1, Schultes HJ2, Fricke FU1
1Fricke & Pirk GmbH, Nuremberg, Germany; 2Novartis
Pharma GmbH, Nuremberg, Germany
OBJECTIVE: Cyclosporine introduction for immunosup-
pressive therapy in the early 1980s has improved graft
survival fundamentally. In the last few years generic
cyclosporines, suggesting similar pharmacokinetics to
branded cyclosporines, were introduced in several
markets. The economic implication with respect to graft
survival rates using branded or generic cyclosporine is
described in the following for Germany. METHODS: The
Collaborative Transplant Study recently (2001) presented
a survey of all actively forwarded one-year-graft-survival
data for kidney transplantation, using either branded or
generic cyclosporine in de-novo transplantations between
1998 and 2000. With 16,800 patients in the branded and
nearly 400 in the generic arm the 10% increase in graft
loss in the generic arm was not statistically signiﬁcant but
clinically relevant. The cost analysis of kidney graft loss
